Listen and follow our podcasts on:

Ipsen

In these two podcasts, medical experts and a patient representative share their perspectives on new Primary Biliary Cholangitis (PBC) data from EASL 2023.

In podcast 1, physicians Dr Emma Culver and Prof. Gideon Hirschfield discuss the evidence of cancer risk associated with PBC, how liver stiffness progression is associated with prognosis; and outcomes and response prediction in second-line therapy.

In podcast 2, CEO of the PBC Foundation, Robert Mitchell-Thain, and autoimmune specialist nurse Kath Houghton explore the impact of PBC symptoms and new instruments for assessing them. They also discuss data highlighting the importance of the current move toward normalisation of liver biomarkers and take a look at some early data on future therapies and therapeutic targets.

Transcripts, with details of the presentations covered, are available for download.

 

Consultant Hepatologist and Honorary Senior Lecturer at the John Radcliffe Hospital and University of Oxford. Clinical Lead for autoimmune and cholestatic liver disease in Oxford. National Committee Chair for UK-IgG4, Steering Committee for British Association for the Study of the Liver Immune-Mediated Liver Disease Special Interest Group and UK-PSC, and Scientific Committee for UK-AIH. Medical Advisory Board for the PBC Foundation and Scientific Advisory Board for PSC Support. Translational funding from the Welcome Trust, NIHR Academy of Medical Sciences, NIHR BRC Oxford, and Oxford Charitable Fund.

Dr Emma Culver has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory Boards for Horizon Therapeutics, Zenus Biopharma, Sanofi, Moderna and Falk Pharma

Presenter fees for Falk Pharma, Horizon and Intercept.

Prof. Gideon Hirschfield has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Prof. Hirschfield received financial support/sponsorship from Advanz, Cymabay, Escient, GSK, Intercept, Ipsen, Miram and Pliant

Kath qualified as a nurse at Ormskirk Hospital, West Lancashire.  She gained experience in major abdominal and vascular theatres at both Ninewells Hospital in Dundee and at Heartlands Hospital in Birmingham.  In 2000 she joined the team at the Royal Victoria Infirmary in Newcastle upon Tyne as an endoscopy nurse before taking up a dual Nurse Specialist/research role with the Upper GI Regional Team at the Northern Oesophageal Gastric Cancer Unit. 

 

Since 2013 Kath has worked in the Hepatology Unit at the Freeman hospital, within the Newcastle Hospitals NHS Foundation Trust, where she has developed an interested in PBC. Currently she works in a dual role covering both research and as the first dedicated Autoimmune Liver Nurse Specialist within the trust, where she focused on patients with PBC.  Kath set up a nurse led PBC telephone clinic and helped to manage the PBC ODN.  She is also part of the PBC Connect educational cohort along with 2 consultants and 2 other nurse specialists from Cambridge, London, Birmingham and Oxford, helping to educate around PBC.

 

CEO at PBC Foundation, Chair of Global Liver Institute’s Paediatric and Rare Liver Disease Council and is also Chair of umbrella organisation, Liver Patients International. PBC Foundation is a UK-based international patient support and advocacy non-profit organisation that supports over 20,000 patients in over 80 countries around the world

Mr Robert Mitchell-Thain has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

The PBC Foundation has received funding from Advanz, Calliditas, Cara, Cymabay, Escient, GSK, Intercept, Ipsen, Mirum, and Umecrine.

Programme summary
Listen to the podcast now
Other episodes of this series
Primary Biliary Cholangitis Highlights from EASL 2023 – Episode 1

Primary Biliary Cholangitis Highlights from EASL 2023 – Episode 1

PBC Highlights from EASL: Episode 1

Current Episode
Share this programme
Ipsen
Supporter Acknowledgement
Ipsen
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

podcast Podcast

Episode

of

episode
  • clock 19 MIN
  • calendar Jul 2024

this xxx bayer
publication Publication
Oncology Rare diseases Endocrinology 
Acromegaly and Neuroendocrine Tumours Global Survey

Paper published in Advances in Therapy

Endorsed by
Wapo INCA
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Aug 2023

Ipsen
video Video
Endocrinology Rare diseases 
Pituitary Updates from ECE & ENDO 2023

Prof. Maria Fleseriu provides 2023 conference data highlights

Experts
Prof. Maria Fleseriu
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jul 2023

Brought to you by COR2ED Medical Affairs in collaboration with Ipsen.
podcast Podcast

Episode

2

of 2

episode
Rare diseases 
Primary Biliary Cholangitis Highlights from EASL 2023 – Episode 2

PBC Highlights from EASL 2023: Episode 2

Experts
Dr Emma Culver, Prof. Gideon Hirschfield, Ms Kath Houghton, Mr Robert Mitchell-Thain
  • download Downloadable
    Resources
  • clock 22 MIN
  • calendar Jun 2023

Ipsen
Rare diseases Pediatrics Endocrinology 
Recognising and Diagnosing Severe Primary IGF-I Deficiency (SPIGFD)

A micro learning programme from paediatric endocrinologists

Experts
Prof. Philippe Backeljauw, Prof. Peter Bang
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2023

Educational programme supported by an Independent Educational Grant from Ipsen
podcast Podcast

Episode

2

of 2

episode
Rare diseases 
Podcast: PBC highlights from the International Liver Congress 2022 – Episode 2

Primary biliary cholangitis highlights from ILC 2022: episode 2

Experts
Prof. Gideon Hirschfield, Prof. Jörn Schattenberg, Prof. Kris Kowdley, Prof. Ana Lleo
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Jun 2022